Detalles de la búsqueda
1.
Long-term outcomes of neoadjuvant trastuzumab emtansine + pertuzumab (T-DM1 + P) and docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP) for HER2-positive primary breast cancer: results of the randomized phase 2 JBCRG20 study (Neo-peaks).
Breast Cancer Res Treat;
2024 May 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-38767786
2.
Effectiveness and safety of granulocyte colony-stimulating factor priming regimen for acute myeloid leukemia: A systematic review and meta-analysis of the Clinical Practice Guideline for the use of G-CSF 2022 from the Japan Society of Clinical Oncology.
Int J Clin Oncol;
2024 May 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-38755516
3.
Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): patient-reported outcomes from a randomised, open-label, multicentre, phase 3 trial.
Lancet Oncol;
25(5): 614-625, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38697155
4.
Therapeutic use of granulocyte colony-stimulating factor (G-CSF) in patients with febrile neutropenia: a comprehensive systematic review for clinical practice guidelines for the use of G-CSF 2022 from the Japan Society of Clinical Oncology.
Int J Clin Oncol;
2024 May 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-38696053
5.
Effectiveness of G-CSF in chemotherapy for digestive system tumors: a systematic review of the Clinical Practice Guidelines for the Use of G-CSF 2022 delineated by the Japan Society of Clinical Oncology.
Int J Clin Oncol;
2024 Apr 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-38578596
6.
Comparison between a single dose of PEG G-CSF and multiple doses of non-PEG G-CSF: a systematic review and meta-analysis from Clinical Practice Guidelines for the use of G-CSF 2022.
Int J Clin Oncol;
2024 Apr 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-38649648
7.
Effectiveness and safety of primary prophylaxis of granulocyte colony-stimulating factor during dose-dense chemotherapy for urothelial cancer: Clinical Practice Guidelines for the Use of G-CSF 2022.
Int J Clin Oncol;
29(5): 545-550, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38517658
8.
Trastuzumab deruxtecan for human epidermal growth factor receptor 2-low advanced or metastatic breast cancer: recommendations from the Japanese Breast Cancer Society Clinical Practice Guidelines.
Breast Cancer;
31(3): 335-339, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38433181
9.
Effectiveness and safety of primary prophylaxis of G-CSF during chemotherapy for prostate cancer, Japanese clinical guideline for appropriate use of G-CSF: clinical practice guidelines for the use of G-CSF 2022.
Int J Clin Oncol;
29(5): 559-563, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38538963
10.
Effectiveness and safety of primary prophylaxis with G-CSF after induction therapy for acute myeloid leukemia: a systematic review and meta-analysis of the clinical practice guidelines for the use of G-CSF 2022 from the Japan society of clinical oncology.
Int J Clin Oncol;
29(5): 535-544, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38494578
11.
Optimal timing of prophylactic pegylated G-CSF after chemotherapy administration for patients with cancer: a systematic review and meta-analysis from Clinical Practice Guidelines for the use of G-CSF 2022.
Int J Clin Oncol;
29(5): 551-558, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38526621
12.
Analysis of Adverse Events Associated with Trastuzumab Deruxtecan in Patients with Gastric and Breast Cancer: A Retrospective Study.
Biol Pharm Bull;
47(2): 411-416, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38346748
13.
Effectiveness and safety of primary prophylaxis with G-CSF for lung cancer: a systematic review and meta-analysis to develop clinical practice guidelines for the use of G-CSF 2022.
Int J Clin Oncol;
29(4): 355-362, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38353907
14.
Patient-Reported Outcomes in OlympiA: A Phase III, Randomized, Placebo-Controlled Trial of Adjuvant Olaparib in gBRCA1/2 Mutations and High-Risk Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer.
J Clin Oncol;
42(11): 1288-1300, 2024 Apr 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-38301187
15.
Correction to: Clinical and imaging features of interstitial lung disease in cancer patients treated with trastuzumab deruxtecan.
Int J Clin Oncol;
29(1): 78-79, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-37897554
16.
Clinical and imaging features of interstitial lung disease in cancer patients treated with trastuzumab deruxtecan.
Int J Clin Oncol;
28(12): 1585-1596, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-37787866
17.
Efficacy and safety of pegfilgrastim biosimilar MD-110 in patients with breast cancer receiving chemotherapy: Single-arm phase III.
Cancer Med;
12(20): 20242-20250, 2023 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37824431
18.
Primary ovarian insufficiency associated with lenvatinib therapy in a patient with hepatocellular carcinoma: A case report.
Oncol Lett;
26(4): 450, 2023 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-37720675
19.
Efficacy, safety, and biomarker analysis of nivolumab in combination with abemaciclib plus endocrine therapy in patients with HR-positive HER2-negative metastatic breast cancer: a phase II study (WJOG11418B NEWFLAME trial).
J Immunother Cancer;
11(9)2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37709297
20.
Influence of menopause on chemotherapy-induced nausea and vomiting in highly emetogenic chemotherapy for breast cancer: A retrospective observational study.
Cancer Med;
12(18): 18745-18754, 2023 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-37676079